Today, Owkin has unveiled its precision AI drug pipeline in oncology & immunology. To accelerate time-to-patient impact, Owkin has in-licensed OKN4395, a highly selective and potent EP2/4 dual antagonist from Idorsia that will enter Phase 1 trials in early 2025. Our cutting-edge AI engines will maximize its probability of success by identifying the optimal indication and patient sub-population and de-risk its ongoing clinical development. Discover our Tx and Dx pipeline at owkin.com/pipeline
Owkin
Recherche en biotechnologie
New York, NY 39 534 abonnés
We use AI to find the right treatment for every patient.
À propos
Owkin est une startup franco-américaine qui utilise l'intelligence artificielle pour trouver le bon traitement pour chaque patient. Notre objectif est d'utiliser l'IA pour découvrir et développer de meilleurs traitements pour des besoins médicaux non satisfaits, en commençant par la lutte contre le cancer. Nous utilisons l'IA pour identifier de nouveaux candidats médicaments, dé-risquer et accélérer les essais cliniques et construire des outils de diagnostic qui améliorent les résultats des patients. Grâce à l'apprentissage fédéré (federated learning), une structure d'IA collaborative pionnière, Owkin permet aux partenaires médicaux et biopharmaceutiques d'obtenir des informations précieuses à partir d'ensembles de données cloisonnés, tout en protégeant la vie privée des patients et en sécurisant les données exclusives. Owkin a été cofondé en 2016 par Thomas Clozel MD, médecin de recherche clinique et ancien professeur adjoint en onco-hématologie clinique, et Gilles Wainrib, pionnier dans le domaine de l'apprentissage automatique en biologie. Owkin a levé plus de 255 millions de dollars et est devenue une "licorne" - une startup valorisée à plus d'un milliard de dollars - en novembre 2021 grâce à un investissement de 180 millions de dollars de la société biopharmaceutique française Sanofi.
- Site web
-
https://www.owkin.com
Lien externe pour Owkin
- Secteur
- Recherche en biotechnologie
- Taille de l’entreprise
- 201-500 employés
- Siège social
- New York, NY
- Type
- Société civile/Société commerciale/Autres types de sociétés
- Fondée en
- 2016
- Domaines
- artificial intelligence, omics technology, oncology, drug discovery, medical research, biomedical images, real-world data, real world evidence, radiology, clinical data, federated learning, covariate adjustment, clinical tools, digital pathology, healthcare, diagnostic solutions, biomarkers, precision medicine et data science
Lieux
Employés chez Owkin
-
Jean-Philippe Vert
Chief R&D at Owkin / Co-founder at Bioptimus / Use AI to unravel biology and find the right treatment for every patient
-
Helen Burns
Freelance Resourcing Director | Talent Acquisition Leader | Coach delivering impact through change | Flow Game Host
-
Michaël Auffret
-
Rodney Hawkins
Nouvelles
-
🚲 It’s time for 'A Few of Our Favorite Things' — Meet our Owkinaute Alec Davi and his custom-built bike. Complete with a shark attack seat and a quirky broken bell, this unique ride turns heads wherever it goes. Learn more about Owkin, and what makes us so special: https://lnkd.in/ekqghTTp #LifeAtOwkin
-
It’s amazing what can be done in just 5 months! Congratulations to the Bioptimus team for the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology. 🧬 We’re excited to use this model to accelerate our diagnostics and drug discovery and development work. Learn more at: https://lnkd.in/gsZEHEx3
🚀 Less than five months after our launch, we’re excited to announce the release of H-optimus-0, the world’s largest open-source AI foundation model for pathology! With 1.1 billion parameters, H-optimus-0 is trained on a proprietary dataset of several hundreds of millions of images extracted from over 500,000 histopathology slides across 4,000 clinical practices. This sets a new benchmark for state-of-the-art performance in several critical medical diagnostic tasks, from identifying cancerous cells to detecting genetic abnormalities in the tumor. You can access the model, detailed documentation, and research findings on our GitHub repository: https://lnkd.in/gnpxw3wT Read our press release: https://lnkd.in/gPzr47qN
-
🎬 Watch MSIntuit® CRC in action — discover its capabilities, features and functionalities, with comprehensive insights for microsatellite instability (MSI) testing. MSIntuit® CRC is a CE-marked AI diagnostic that provides a MSI prescreen approach with digital pathology. Learn more about MSIntuit CRC https://lnkd.in/gy5ubAZs
-
🌐 Join us today at the STAT webinar where our Chief Diagnostics Officer, Meriem Sefta, will speak on a panel discussion 'Is this the era of AI diagnostics?' alongside Kunal Chokshi and Gazala Khan. The webinar will be held on July 9th from 5:00 to 5:30 pm CEST. Register today https://lnkd.in/e3rTcATx
-
-
Owkin has expanded its footprint into the DACH regions, partnering with nine hospitals in Germany, Switzerland, and Austria. Owkin will bring its world-class data access and AI to the forefront of drug discovery and development, analyzing multimodal patient data in a privacy-enhanced way. Learn more here: https://lnkd.in/ePAwi_Q7
-
Have you ever wondered what goes on behind the scenes at Owkin? 👀 Take a sneak peek into #LifeAtOwkin and the Slack channels that make us laugh, inspire us, and brighten our workdays while bringing Owkinautes together. From ping pong to pets, there's something for everyone to join! Learn more about Owkin https://lnkd.in/e5CYvKkG
-
Did you know that there is a simple and standardized approach to detect TLS across tumor types from digital H&E slides? With a sensitivity of 97%, TLS Detect has the potential to screen for TLS presence in tumors in a research setting. Help us understand your needs for TLS detection in your research by filling out our quick survey 🏆 First five people to complete the 5-question survey will receive a “Humanity” book. Fill out the survey https://lnkd.in/eiPsY_dq
Ce contenu n’est pas disponible ici
Accédez à ce contenu et plus encore dans l’application LinkedIn
-
Introducing TLS Detect RUO – an AI research tool designed to detect the presence of tertiary lymphoid structures (TLS) across various tumor types using digital H&E slides. TLS is a novel biomarker for assessing survival risk and immunotherapy response in untreated cancer patients. With a sensitivity of 97%, TLS Detect screens for TLS presence in tumors in a research setting. TLS Detect was developed with annotated data from Cancer Comprehensive Center and long-time partner of Owkin, Institut Bergonié. Visit the TLS Detect product page https://lnkd.in/eBqzUt23 Help us understand the needs of TLS detection in your research https://lnkd.in/eiPsY_dq #tertiarylymphoidstructures #tls
-
-
Owkin’s AI is accelerating and augmenting biology: This month, we’re exploring how Owkin is augmenting #biology with PACpAInt – our #AI model to identify subtypes of pancreatic adenocarcinoma from whole slide digital images. 👇 The AI model robustly predicts the known ‘classical’ and ’basal’ subtypes, which can accelerate how doctors choose the best treatment options for every patient. PACpAInt also identified two novel ‘mixed’ and ‘intermediate’ subtypes, highlighting important heterogeneity within the tumour, which paves the way to new therapeutic strategies in the future. Take a look at the original publication: https://lnkd.in/echG-6Q7
-